Bayer

Bayer remains one of the most polarizing stocks in the DAX in 2026. CEO Bill Anderson, in post since June 2023, has run the group in perpetual reform mode. The 2025 launch of Dynamic Shared Ownership (DSO) — the dissolution of classical middle management — was supposed to cut 5,500 roles, but landed only partly. As of Q1/2026: revenue €14.4B (-2.8% YoY), core EPS €2.18 (vs. €2.02 consensus), free cash flow €1.1B (a sharp improvement vs. -€1.3B in Q1/2025).

The market has two dominant 2026 worries: (1) Glyphosate litigation: the US plaintiff pipeline still has roughly 67,000 open cases, with cumulative settlement payments at $11.2B through Q1/2026. Anderson announced a ‘single-event settlement path’ in February 2026 — a federal-level resolution intended to bury the risk for good. (2) Aspirin Plus C recalls in China cost the consumer-health segment €800M of reputational damage, which the margin recovery in Crop Science has not offset.

On the pharma pipeline, Bayer holds two real 2026 hopes: Asundexian (factor-XIa inhibitor, stroke prevention) is in Phase 3 with a mid-2027 approval pathway — peak sales estimates run €5–7B. And Acoramidis (ATTR cardiomyopathy, in-licensed from BridgeBio) starts full European commercialization in 2026.

Bayer is a textbook ‘activist battleground’ in 2026: Bluebell Capital still holds 0.9% and has been pushing for a break-up into Pharma, Crop Science, and Consumer Health since 2023. Inclusive Capital Partners (Jeff Ubben) opened a similar position in Q4/2025. Anderson responded in March 2026 with a ‘strategic review’ announcement — final word in Q4 2026.

Traditional long side: Allianz Global Investors (the home-market anchor) is steady at 4.1%, Vanguard at 3.0%, Norges Bank at 2.8%. Notable: Capital Group dropped below 1% in 2026 for the first time since 2019 — the loss of an important US-mandate sponsor.

Bayer trades at 5.8× 2026 P/E — one of the lowest valuations in the entire DAX. On 2026 core EPS of €4.80, the earnings yield is 17%. SOTP valuation puts the three segments at: Pharma €38–45B, Crop Science €22–30B, Consumer Health €10–13B. Total €70–88B EV minus €35B net debt = €35–53B equity, i.e. €36–54 per share. Current price (~€28) sits well below SOTP — a 22–48% holding discount. The stock is a high-conviction special-situations play; the dominant question is litigation, not operations.

1. Q3 2026: Expected Asundexian Phase 3 topline data (OCEANIC-AF and OCEANIC-STROKE). Positive readouts could trigger a 15–20% single-day rally.
2. Q4 2026: Anderson's strategic review verdict on group break-up. The market will price between ‘break-up coming’ and ‘structural optimization only’.
3. H1 2027: Possible federal glyphosate settlement announcement following the J&J talc template. Would be the definitive de-risking event since the 2018 Monsanto deal.

Bayer is not for weak nerves — the stock can swing 8% in a day on a single litigation headline. But the fundamental asymmetry in 2026 finally favors the bull case: 30%+ SOTP discount, Asundexian optionality, mounting reform pressure on Anderson. I hold 2.5% portfolio weight, built over 18 months via DCA, and consciously accept the high volatility. If you want pharma beta without the Bayer-specific tail, prefer Novo Nordisk or Roche.